Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
NT2-H5228 | Human | Human TrkB / NTRK2 Protein, His Tag | ![]() |
![]() ![]() |
|
NT2-H5254 | Human | Human TrkB / NTRK2 Protein, Fc Tag | ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Entrectinib | NMS-E628; RG-6268; RXDX-101 | Approved | Nerviano Medical Sciences, Ignyta Pharma, Chugai, Genentech | Entrectinib | 日本 | Solid tumours | 中外制药 | 2019-06-18 00:00:00.0 | Solid tumours, ROS1-positive non-small cell lung cancer (NSCLC) | Details |
Cabozantinib S-malate | XL-184; BMS-907351,BMS907351,XL184,XL 184,BMS 907351 | Approved | Exelixis, Ipsen, Takeda | COMETRIQ | fda | Medullary thyroid cancer (MTC) | EXELIXIS | 2012-11-29 | Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Medullary thyroid cancer (MTC), Hepatocellular carcinoma (HCC) | Details |
Larotrectinib sulfate | ARRY-470; LOXO-101 | Approved | Array BioPharma, Loxo Oncology, Bayer | VITRAKVI | fda | Solid tumours | BAYER HLTHCARE | 2018-11-26 | Solid tumours | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Repotrectinib | TPX-0005,TPX0005,TPX 0005 | Phase Ⅱ | Turning Point Therapeutics | Non small cell lung cancer (NSCLC), Solid tumours | Details |
ACD-856 | ACD-856 | Phase Ⅰ | AlzeCure Pharma AB | Alzheimer's disease (AD) | Details |
Brain-derived neurotrophic factor | Phase Ⅱ | Max Planck Institute of Experimental Medicine, Sumitomo Dainippon, Amgen, Regeneron Pharmaceutical | Amyotrophic lateral sclerosis (ALS) | Details | |
BN-201 | BN-201 | Phase Ⅰ | Bionure | Optic neuritis, Neuromyelitis optica (NMO) | Details |
Altiratinib | DCC-22701; DCC-2701; DP-5164; T-678746713 | Phase Ⅰ | Deciphera | Solid tumours | Details |
CE-245677 | CE-245677 | Phase Ⅰ | Pfizer | Cancer | Details |
TQB-3558 | TQB-3558 | Phase Ⅰ | Chiatai Tianqing (CTTQ) | Advanced solid tumors | Details |
DS-6051 | DS-6051; DS-6051a; DS-6051b; AB-106,DS6051b,DS6051a,DS6051,AB106 | Phase Ⅱ | Daiichi Sankyo, AnHeart Therapeutics | Non small cell lung cancer (NSCLC), Solid tumours | Details |
Lestaurtinib | A-154475.0; CEP-701; KT-5555; SP-924; SPM-924 | Phase Ⅲ | Kyowa Hakko Kirin, Cephalon | Acute lymphoblastic leukaemia (ALL) | Details |
HG-030 | HG-030,HG030 | Phase Ⅰ | HitGen | Solid tumours | Details |
PLX-7486 | PLX-7486; PLX7486-TsOH | Phase Ⅱ | Daiichi Sankyo | Solid tumours, Pancreatic cancer | Details |
ACD-855 | ACD-855 | Phase Ⅰ | AlzeCure Pharma AB | Alzheimer's disease (AD) | Details |
This web search service is supported by Google Inc.